A blinded, controlled trial of objective measurement in Parkinson's disease.

NPJ Parkinsons Dis · 2020 · PMC7680151 · PMID 33298955

Europe PMC DOI

hedged sentences

0.0550

closest p · 1.1× alpha

0.0700

boldest claim

The sentences

failed to reach significanceP = 0.055so close (0.05 < p ≤ 0.1)

SENS PD failed to reach significance (1.5, 95% CI 1.5–3.0, P = 0.055) and PDQ39 was not significantly different (3.3, 95% CI 1.8–8.4, P = 0.21).

also in 4,113 other papers

approached significanceP = 0.07so close (0.05 < p ≤ 0.1)

In those who were out of target, there was a significant difference between the PKG+ and PKG− arm for MDS-UPDRS Total (7.3, 95% CI 3.4–11.2, P = 0.002) and III (5.3, 95% CI 2.4–8.3, P = 0.0004), but not for PDQ39 and SENS PD (although these approached significance in people who were bradykinetic at onset: P = 0.07 and P = 0.05 respectively).

also in 8,237 other papers

fell just short of significanceP = 0.07so close (0.05 < p ≤ 0.1)

The difference between the first and last visit were then calculated for each arm and then compared (Table 3 , All participants PKG+ (1st–last visit) vs PKG− (1st–final visit)): the MDS-UPDRS III was significantly different (4.1, 95% CI 1.3–6.9, P = 0.01) but the difference for MDS-UPDRS Total, while still large, fell just short of significance (4.4, 95% CI 0.6–8.4, P = 0.07).

also in 102 other papers

just failed to reach statistical significanceP = 0.07so close (0.05 < p ≤ 0.1)

While the change in PDQ39 score in the PKG+ arm just failed to reach statistical significance ( P = 0.07), the mean change in this study (4.7) compares favourably with that of the best change (~2.2) from levodopa 7 and the 17% change in PDQ39 in this study also compares favourably with that seen in DBS (24%) 9 .

also in 203 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.